NEJM publishes Revolution Medicines Phase 1/2 data on RASONQUE™ in NSCLC
Revolution Medicines said The New England Journal of Medicine has published Phase 1/2 clinical data for RASONQUE (daraxonrasib) in metastatic non-small cell lung cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
NEJM publishes RVMD Phase 1/2 data on RASONQUE in metastatic NSCLC
NEJM published Phase 1/2 clinical data on Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic non-small cell lung cancer.